Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1391 ARTÍCULOS , VIENDO DEL 1336 AL 1350

Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease

Cummings J, Zhong K.

Clin Pharmacol Ther. 2015 Nov;98(5):483-5. doi: 10.1002/cpt.190. Epub 2015 Aug 31.

Parkinson's disease dementia: Diagnostic criteria and risk factor review

Vasconcellos LF, Pereira JS.

J Clin Exp Neuropsychol. 2015;37(9):988-93. doi: 10.1080/13803395.2015.1073227.

Beta Amyloid Hallmarks: From Intrinsically Disordered Proteins to Alzheimer's Disease

Korsak M, Kozyreva T.

Adv Exp Med Biol. 2015;870:401-21. doi: 10.1007/978-3-319-20164-1_14.

The Concept of Subconsciousness in Alzheimer's and Parkinson's Diseases

Agid Y.

J Parkinsons Dis. 2015;5(3):643-5. doi: 10.3233/JPD-150573.

The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact

Haeffner-Cavaillon N, Devos P, Ledoux S, Ménard J.

Alzheimers Res Ther. 2015 Sep 26;7(1):60. doi: 10.1186/s13195-015-0144-z.

Changes in Nutritional Status after Deep Brain Stimulation of the Nucleus Basalis of Meynert in Alzheimer's Disease--Results of a Phase I Study

Noreik M, Kuhn J, Hardenacke K, Lenartz D, Bauer A, Bührle CP, Häussermann P, Hellmich M, Klosterkötter J, Wiltfang J, Maarouf M, Freund HJ, Visser-Vandewalle V, Sturm V, Schulz RJ.

J Nutr Health Aging. 2015 Oct;19(8):812-8. doi: 10.1007/s12603-015-0595-8.

Semantic profiles in mild cognitive impairment associated with Alzheimer's and Parkinson's diseases

Guidi M, Paciaroni L, Paolini S, Scarpino O, Burn DJ.

Funct Neurol. 2015 Apr-Jun;30(2):113-8. doi: 10.11138/fneur/2015.30.2.113.

Using Administrative Data to Examine Health Disparities and Outcomes in Neurological Diseases of the Elderly

Willis AW.

Curr Neurol Neurosci Rep. 2015 Nov;15(11):75. doi: 10.1007/s11910-015-0595-4.

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease

Gui Y, Liu H, Zhang L, Lv W, Hu X.

Oncotarget. 2015 Nov 10;6(35):37043-53. doi: 10.18632/oncotarget.6158.

Association of type 2 diabetes GWAS loci and the risk of Parkinson's and Alzheimer's diseases

Chung SJ, Kim MJ, Kim J, Ryu HS, Kim YJ, Kim SY, Lee JH.

Parkinsonism Relat Disord. 2015 Dec;21(12):1435-40. doi: 10.1016/j.parkreldis.2015.10.010. Epub 2015 Oct 20.

Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease

Goldman JG, Aggarwal NT, Schroeder CD.

Neurodegener Dis Manag. 2015 Oct;5(5):425-43. doi: 10.2217/nmt.15.34. Epub 2015 Oct 30.

Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised

Sobreira E, Pena-Pereira MA, Eckeli AL, Sobreira-Neto MA, Chagas MH, Foss MP, Cholerton B, Zabetian CP, Mata IF, Tumas V.

Arq Neuropsiquiatr. 2015 Nov;73(11):929-33. doi: 10.1590/0004-282X20150156.

A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders

Gendelman HE, Mosley RL.

J Neuroimmune Pharmacol. 2015 Dec;10(4):645-50. doi: 10.1007/s11481-015-9639-4. Epub 2015 Oct 31.

Neuroethical implications of deep brain stimulation in degenerative disorders

Ovadia D, Bottini G.

Curr Opin Neurol. 2015 Dec;28(6):598-603. doi: 10.1097/WCO.0000000000000263.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias